Sections

Alphabetical list:

A B C D E F G H I J K L M N O P R S T U V W X Y Q Z 1 2 3 4 5 6 7 8 9

News: November 29, 2009

Rituximab May Offer Hope To Severe Graves' Eye Disease Patients

November 29, 2009

There may be hope for patients with severe Graves' eye disease in the form of treatment with the drug rituximab.

This news comes from U-M Kellogg Eye Center who's oculoplastics specialist Raymond S. Douglas, M.D., Ph.D. reports on the potential of the drug in the online October issue of Ophthalmology.

Graves' eye disease is an autoimmune disease that causes inflammation and fatty deposits in the eye muscles and connective tissue surrounding the eye.

Douglas reports on the progress of six patients (four women, two men) who had not responded to treatment using systemic corticosteroids. The patients were then treated with rituximab. All patients responded within 2 months with the clinical activity score (CAS) improving from5.50.8 to 1.30.5. The eye disease remained quiescent in all with the positive results being sustained at 4-6 months after treatment.

Vision improved bilaterally in all 4 patients with dysthyroid optic neuropathy (DON). Proptosis remained stable (Hertel measurement, 243.7 mm before therapy and 23.63.7 mm after therapy; P = 0.17).

"These patients had already received the maximum level of steroid treatment," says Douglas. "Treatment with rituximab calmed inflammation, stopped progression of the disease, and saved the patients from having to undergo surgery."

Graves' disease (also known as thyroid eye disease) is an autoimmune condition in which white blood cells attack the thyroid gland which responds by secreting an excess amount of thyroid hormone. The hypermetabolic state is characterized by fast pulse/heartbeat, palpitations, profuse sweating, high blood pressure, irritability, fatigue, weight loss, heat intolerance, and loss of hair and alterations in hair quality.

Rituximab has been used to treat patients with other autoimmune diseases, including rheumatoid arthritis and in non-Hodgkin's B-cell lymphoma. The drug works by depleting B cells - the body's normal antibody-producing cells - that appear to go awry in autoimmune diseases.

"Treatment of the inflammatory component of Graves' eye disease has not advanced appreciably over several decades," says Douglas. High-dose steroids, sometimes in combination with orbital radiation, are still the first line treatment. But, says Douglas, "These are imperfect options because inflammation often recurs when the treatment ends." He is hopeful that rituximab can offer sustained improvement. Douglas observes that the results from a small case series must be viewed with some caution. But given the substantial benefits for patients treated with rituximab, he sees good reason to proceed with a large-scale clinical trial to test this promising new drug.

Source

Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy; Ophthalmology, 2009; Chong et al.; DOI: 10.1016/j.ophtha.2009.05.029


University of Michigan Health System Newsroom



Archive issues: (50)

Archive list: 1 2 3 4 5 6 7 8 9 10 11 12 13 [14] 15 16 17

November 5, 2009 | To Quit Smoking, Use Patch Plus Lozenge

Out of five different smoking cessation methods, the nicotine patch plus lozenges proved to be the most effective, according to research published in the November issue of Archives of General Psychiatry. The study is the first to ...

November 4, 2009 | Soft Drinks Take a Toll on Your Health

The only positive thing one can say about soft drinks is that they taste good, but the price people pay in terms of their health for that good taste can be high. When we look at the benefits and risks associated with soft drink consumption, the risk side of the equation is clearly the winner-and consumers are the losers.  For example, a meta-analysis of 88 studies conducted by researchers at Yale University found a clear association between ...

November 3, 2009 | Yoga Benefits Cancer Patients

Some of the major cancer centers across the country, including MD Anderson, Memorial Sloan-Kettering, and Dana-Farber Cancer Institute, now offer their patients yoga as a complementary therapy in an effort to provide a more integrative approach to care. In addition, ...

Archive list: 1 2 3 4 5 6 7 8 9 10 11 12 13 [14] 15 16 17

Related articles:

Chronic bacterial prostatitis - prognosis

  Over time, the relapse rate is high, exceeding 50%. A 2007 study showed that repeated courses of combination antibiotics may eradicate infection in 83.9% of patients with clinical remission extending throughout a follow-up period of 30 months for 94% of these patients.    

Section: Prostatitis

Treatment - diet

  The foundation of therapy is a modification of diet to help patients avoid those foods which can further irritate the damaged bladder wall. Common offenders are highly spiced or acidic foods and include alcohol, coffees, teas, herbal teas, green teas, all sodas (particularly diet), concentrated fruit juices, tomatoes, citrus fruit, cranberries, the B vitamins, vitamin C, monosodium glutamate, chocolate, and potassium-rich foods such as bananas. Most IC/PBS support ...

Section: Interstitial cystitis

News

December 20, 2009

Wii, Xbox 360 and Other Video Games Offer Some Benefits

Wii, Xbox 360, PlayStation, and other video games are hot on holiday gift lists, but some parents wonder whether these games offer any benefits or are detrimental to kids. The results of a new study may put some minds at ease, while others may ...

December 18, 2009

Should You Be Shoveling Snow?

Yes, the weather outside is frightful, and soon you will have to think about shoveling snow. But should you be the one doing the work? Who should and should not shovel snow, and how can you do it ...

December 17, 2009

Athletes who take NSAID's to prevent pain may be doing more harm than good

According to Stuart Warden, a researcher who studies musculoskeletal health and sports medicine, athletes who ritualistically take NSAID's to prevent post event and workout soreness and inflammation may be ...

Blogroll